Phase I Study of VENT-02 in Neuroinflammatory and Neurodegenerative Diseases in Healthy Volunteers

The primary objective of the study is to evaluate the safety and tolerability of **VENT-02** in healthy volunteers. This is crucial for determining the potential of **VENT-02** as a therapeutic agent for **neuroinflammatory and neurodegenerative diseases**. Understanding the safety profile in a healthy population is a foundational step before considering further clinical trials in patients with these conditions.

The clinical trial involves participants diagnosed with **neuroinflammatory and neurodegenerative diseases**. The study population includes both male and female subjects, with an age range that encompasses both adults and older adults. The trial population was selected to include a vulnerable population, although specific details regarding the selection process or lifestyle considerations such as diet, physical activity, or habits have not been provided. The sponsor has not disclosed the total number of participants involved in the study. Key inclusion or exclusion criteria have not been specified, and the main objective of the trial remains unspecified in the provided data.

The clinical trial is designed to evaluate the safety and tolerability of VENT-02 in healthy volunteers, focusing on **neuroinflammatory and neurodegenerative diseases**. This is a Phase 1 trial, which is typically the first stage of testing in human subjects. The trial employs a randomized, double-blind, and controlled design to ensure unbiased results and to maintain the integrity of the data collected. The estimated duration of the trial is from June 24, 2023, to April 1, 2024, allowing for comprehensive data collection and analysis.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit is crucial for ensuring that only suitable candidates are enrolled in the study. Following the screening, participants will attend multiple follow-up visits, which are scheduled to monitor their health and any potential side effects of the investigational product. These visits are essential for collecting data on the pharmacokinetics and pharmacodynamics of VENT-02. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the overall safety and efficacy of the treatment.

The expected length of participant involvement is approximately ten months, from the initial screening to the end-of-study visit. However, certain conditions may lead to early termination from the study, such as adverse reactions, non-compliance with study protocols, or withdrawal of consent by the participant. The trial is conducted under strict ethical guidelines, ensuring the safety and well-being of all participants throughout the study duration.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided dataset. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is June 24, 2023, with an anticipated end date of April 1, 2024. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. These assessments may include the use of validated scales, laboratory tests, or patient-reported outcomes to measure changes in relevant clinical parameters. The data collection and analysis will be conducted according to the trial's protocol, ensuring rigorous and systematic evaluation of the investigational product's effects. The trial's findings will contribute to the understanding of the investigational product's potential therapeutic benefits and inform subsequent phases of clinical research.